Our pipeline.
ABCL635 is an investigational antibody drug candidate being developed for the non-hormonal treatment of VMS (commonly known as hot flashes) due to adjuvant endocrine therapy (AET) for breast cancer. ABCL635 specifically targets NK3R, a complex transmembrane protein found on hypothalamic KNDy neurons that helps regulate body temperature.
ABCL635 is also being developed for the treatment of VMS due to menopause and VMS due to androgen deprivation therapy (ADT) for prostate cancer.
ABCL635 is an investigational antibody drug candidate being developed for the non-hormonal treatment of VMS (commonly known as hot flashes) due to androgen deprivation therapy (ADT) for prostate cancer. ABCL635 specifically targets NK3R, a complex transmembrane protein found on hypothalamic KNDy neurons that helps regulate body temperature.
ABCL635 is also being developed for the treatment of VMS due to menopause and VMS due to adjuvant endocrine therapy (AET) for breast cancer.
ABCL992 is a next-generation investigational antibody drug being developed for the treatment of moderate and severe VMS. ABCL992 is a half-life extended analog of ABCL635 designed to support less frequent intervals. ABCL992 specifically targets NK3R, a complex transmembrane protein found on hypothalamic KNDy neurons that helps regulate body temperature.
ABCL385 is an investigational antibody drug candidate for an undisclosed indication in oncology.
ABCL646 is a potential first-in-class investigational antibody drug candidate for an undisclosed ion channel target and undisclosed indication.
From target to the clinic. Our platform integrates biology, computation, and engineering to develop impactful antibody-based medicines.
People
connected.
This is a place that exists to push the limits of science and technology. A place focused on delivering breakthrough medicines that alleviate suffering, extend lives, and improve health.
With
purpose.
In the end, our success will be measured by the impact of our medicines.
Tiffany Mintah
Learning and Development Program Manager
AbCellera’s commitment to people, teams, and relationships is what drew me towards the company. I’m surrounded by brilliant, kind, and down-to-earth people every day, and I’m excited to contribute to this team.
Allie Goodman
Associate Scientific Director
Our family relocated to Vancouver from Boston — it’s a great place to raise our kids. We’re big hikers, bikers, and skiers, and take every chance we get to drive 25 min to the mountains and go on an adventure!
Peri Selevos
Senior Scientist
I love being part of a team where everyone’s ideas are heard. We work together to solve problems and make things happen, which makes coming to work something I actually look forward to—even on Mondays!
Callum Costello
Scientist I
There’s a tangible impact from the work I do as we move towards bringing medicines to patients. And I get to do that inspirational work in Vancouver, where I’m surrounded by incredible nature!
We have grown from six scientists in a lab to a company of ~600 people with fully integrated capabilities for creating first-in-class and best-in-class antibody medicines.
Since 2015, we have worked with more than 40 partners on 100+ antibody drug programs, solving some of the most difficult problems in the industry.
We have built a competitive advantage in the creation of antibody-based medicines. We are using our technology platform to advance programs involving complex transmembrane proteins, bispecifics, and antibody drug conjugates.
We hire for character and intelligence.
Driven by science.